Ackman's Pershing Square Scaled Back Allergan, Added To Platform Specialty Products In Q4
From his head-to-head battle with Carl Icahn over whether or not Herbalife Ltd (NYSE: HLF) is a pyramid scheme, to his lawsuit against the U.S. government over its treatment of Fannie Mae (NASDAQOTCBB: FNMA) and Freddie Mac (NASDAQOTCBB: FMCC), billionaire investor Bill Ackman has never been afraid to take an aggressive stance.
Ackman is founder and CEO of Pershing Square Capital Management LP, and many investors that follow the fund's moves have been eagerly awaiting the latest 13-F filing for the fourth quarter.
Here’s a breakdown of the moves.
Scaling Back Allergan Inc (NYSE: AGN)
Pershing reduced its position in Allergan by more than two million shares in Q4 down to 26,635,978 shares. With a value of over $5.6 billion, Allergan remains Pershing’s largest holding by a wide margin.
Adding To Platform Specialty Products Corp (NYSE: PAH)
Pershing increased its stake in Platform by over nine million shares in the quarter. As of the Q4 filing, the position is valued at just over $992 million.
Adding To Zoetis Inc (NYSE: ZTS)
Pershing increased its stake in Zoetis by more than seven times during Q4. The updated stake is valued at nearly $1.8 billion.
Buying Restaurant Brands Intl Inc (NYSE: QSR)
The only totally new position in Pershing’s 13-F is a more than 38 million-share stake in Restaurant Brands. The new holding is valued at nearly $1.5 billion.
To see the rest of Pershing’s holdings, the company’s full 13-F filing can be found here.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.